CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023 09:05 ET | Biogen Inc.
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
Global Ataxia Market Size To Grow USD 69,889.4 Million By 2030 | CAGR of 9.5%
November 28, 2022 13:30 ET | SPHERICAL INSIGHTS LLP
New York, United States , Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Global Ataxia Market Size to grow from USD 30,880.5 million in 2021 to USD 69,889.4 million by 2030, at a Compound Annual Growth Rate...
Facts & Factors.jpg
Global Ataxia Market Size Estimated to Acquire USD 46,000.8 Million at a CAGR of 10.2% by 2026 (With COVID-19 Impact Analysis): Facts & Factors
December 21, 2021 06:28 ET | Facts & Factors
New York, United States, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Facts and Factors has published the latest research report titled “Ataxia Market By Disease Type (Idiopathic, Acquired Ataxia, and Genetic...